Bellerophon Therapeutics (BLPH) stock price, revenue and financials

+0.02 (+1.72%)

$67 M

BLPH Mkt cap, 20-Sep-2018

Bellerophon Therapeutics Net income (Q2, 2018)-7.4 M

Bellerophon Therapeutics EBIT (Q2, 2018)-16.4 M

Bellerophon Therapeutics Cash, 30-Jun-201823.4 M

Annual

Quarterly

USD	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q1, 2018	Q2, 2018
R&D expense	9.5 m	8.4 m	7.1 m	5.1 m	4 m	2.5 m	3.3 m	6.4 mwdxefcqufszuzezftuxetqsqxt	12.2 m
General and administrative expense	4.6 m	3.4 m	4.3 m	2 m	1.2 m	1.7 m	1.4 m	2.1 m	4.2 m
Operating expense total	14.1 m	11.9 m	11.4 m	7.1 m	5.2 m	4.2 m	4.8 m	8.5 m	16.4 m
EBIT	(12.9 m)	(11.6 m)	(11.2 m)	(7.1 m)	(5.2 m)	(4.2 m)	(4.8 m)	(8.5 m)	(16.4 m)
Interest income	19 k	27 k	27 k	30 k	22 k	22 k	27 k	99 k	190 k
Income tax expense								5.4 m	5.4 m
Net Income	(12.9 m)	(11.6 m)	(11.1 m)	(7.1 m)	(5.1 m)	(4.2 m)	(19.1 m)	4.1 m	(7.4 m)

Annual

USD	FY, 2016
Cash	14.5 m
Current Assets	26.5 m
PP&E	1.4 m
Total Assets	29.7 m
Accounts Payable	2.8 m
Current Liabilities	6.5 m
Total Liabilities	11.7 m
Additional Paid-in Capital	142.2 m
Retained Earnings	(124.5 m)
Total Equity	18 m
Financial Leverage	1.7 x

Quarterly

USD	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q1, 2018	Q2, 2018
Cash	62.9 m	48.5 m	23.9 m	1.3 m	1.3 m	3.9 m	13.5 m	28.4 m	23.4 m
Current Assets	73.6 m	60.9 m	46.9 m	23.1 m	18.6 m	17.5 m	23.2 m	34.8 m	28.8 m
PP&E	1.6 m	1.5 m	1.8 m	1.7 m	1.6 m	1.5 m	1.3 m	935 k	845 k
Total Assets	75.2 m	62.4 m	49.2 m	31.2 m	26.3 m	22.8 m	25.8 m	35.9 m	29.8 m
Accounts Payable	659 k	966 k	934 k	641 k	2 m	2.2 m	3.9 m	4.6 m	4.1 m
Current Liabilities	12.8 m	11.2 m	8.6 m	7.3 m	6.2 m	4.8 m	6.1 m	8.4 m	9 m
Total Liabilities								33.7 m	37.6 m
Additional Paid-in Capital				131.5 m	132.8 m	134.9 m	144.1 m	176.9 m	178.3 m
Retained Earnings	(67.1 m)	(78.7 m)	(89.9 m)	(107.7 m)	(112.9 m)	(117.1 m)	(143.6 m)	(175.2 m)	(186.7 m)
Total Equity				23.9 m	20.1 m	18 m	800 k	2.2 m	(7.8 m)
Financial Leverage				1.3 x	1.3 x	1.3 x	32.2 x	16.2 x	-3.8 x

Annual

Quarterly

USD	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q1, 2018	Q2, 2018
Net Income	(12.9 m)	(11.6 m)	(11.1 m)	(7.1 m)	(5.1 m)	(4.2 m)	(19.1 m)	4.1 m	(7.4 m)
Depreciation and Amortization								91 k	181 k
Accounts Payable	659 k	966 k	934 k	641 k	2 m	2.2 m	3.9 m
Cash From Operating Activities								(444 k)	(6.1 m)
Cash From Investing Activities									502 k
Cash From Financing Activities								(28 k)	141 k

Report incorrect company information

View Bellerophon Therapeutics profile

Competitors

Healthcare - Public

Deciphera Pharmaceuticals

Healthcare - Public

UNITY Biotechnology

Healthcare - Public

Innovation Pharmaceuticals

Healthcare - Public

Compare competitors